Know Cancer

or
forgot password

Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer, Non-Small Cell Lung Cancer

Thank you

Trial Information

Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria


Eligibility Criteria: - Age 18 years or older - Diagnosis of advanced or metastatic
non-small cell lung cancer (NSCLC) - Have not received any prior chemotherapy - Have not
received radiation therapy or undergone major surgery within the past 2 weeks

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

incidence of infection

Outcome Time Frame:

during treatment

Safety Issue:

No

Principal Investigator

MD

Investigator Role:

Study Director

Investigator Affiliation:

Amgen

Authority:

United States: Food and Drug Administration

Study ID:

20030123

NCT ID:

NCT00094822

Start Date:

July 2003

Completion Date:

February 2006

Related Keywords:

  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Metastatic Cancer
  • Neulasta┬«
  • pegfilgrastim
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location